Die öffentliche Reputation der Pharmaindustrie in den USA im Jahr 2009

Annual RQ. 2009. Summary Report. A survey of the U.S. General pubic using the reputation quotient
Link

Beitrag im Forum Gesundheitspolitik

Physician Professionalism

and Changes in Physician-Industry Relationships From 2004 to 2009. Arch Intern Med 2010;170(20):1820-26.
Campbell EG, Rao SR, DesRoches CM, Iezzoni LI, Vogeli C, Bolcic-Jankovic D, et al.
Abstract

Information from Pharmaceutical Companies

and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review.
PLoS Medicine 19.10.2010 Link

Richard Smith on editors’ conflicts of interest

Der frühere Herausgeber des British Medical Journal schreibt in seinem Blog über Interessenkonflikte von Herausgebern. Link

Anlass ist der Beitrag im PLoS "Conflicts of Interest at Medical Journals". Link

Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study

Conclusions

Publication of industry-supported trials was associated with an increase in journal impact factors. Sales of reprints may provide a substantial income. We suggest that journals disclose financial information in the same way that they require them from their authors, so that readers can assess the potential effect of different types of papers on journals' revenue and impact.

Link

Meldung in aerzteblatt online 27.10.2010

Beitrag im Forum Gesundheitspolitik

Modeling in pharmacoeconomic studies: Funding sources and outcomes

International Journal of Technology Assessment in Health Care 2010), 26: 330-333

Abstract

Conclusions:
The review found a substantial share of studies supported by the pharmaceutical industry, almost all concluding in favor of the drug studied, without any unfavorable conclusions at all. These results confirm also in the field of pharmacoeconomic studies that the best way of limiting confounding factors is by clearly distinguishing assessors from manufacturers and marketers of any new technology.

Industry sponsored bias in cost effectiveness analyses

Editorial BMJ 19.10.2010

European Medicines Agency tightens rules on conflict of interest

BMJ 19.10.2010

Publikationsbias - das Beispiel Reboxetin.

Eyding D, Lelgemann M, Grouven U, Härter M, Kromp M, Kaiser T, et al.
Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. Volltext kostenlos

Editorial der Herausgeberinnen des BMJ

Kommentar R. Steinbrook, JP Kassirer (frühere Herausgeber des New England Journal of Medicine)

Kommentar G. Gigerenzer

Beitrag im Forum Gesundheitspolitik

The Haunting of Medical Journals: How Ghostwriting Sold “HRT”

The Haunting of Medical Journals: How Ghostwriting Sold “HRT”
Adriane J. Fugh-Berman. PLoS Medicine. September 7, 2010

Adriane Fugh-Berman examines documents unsealed in recent litigation to investigate how pharmaceutical companies promoted hormone therapy drugs, including the use of medical writing companies to produce ghostwritten manuscripts and place them into medical journals.

Download